methyl semaglutide SEMAGLUTIDE PEPTIDE VIAL – UMBRELLA

Type 2 Diabetes (Oral Therapy) Orforglipron ACHIEVE-3 directly demonstrated orforglipron 36 mg superiority over oral semaglutide 14 mg for HbA1c reduction (2.2% vs 1.4%) and weight loss (9.2% vs 5.3%) in type 2 diabetes

2 Metformin (MET) is recommended as the first-line treatment for patients with T2DM due to well-established efficacy, safety, low cost, and data demonstrating a reduction in risk of cardiovascular (CV) events

Factors We Consider Prior weight loss experience

Additionally, ongoing monitoring is critical

According to the authors, use of the medications was associated with a lower risk of death from any cause as well as a lower risk of tumor recurrence

Lund ML, Sorrentino G, Egerod KL